Vertex revenues rise as company points to progress beyond cystic fibrosis

27 January 2022
vertex_large

US biotech Vertex Pharmaceuticals (Nasdaq: VRTX) has reported full-year product revenues of $7.57 billion for 2021, a 22% increase compared to 2020, while adjusted earnings were 26% higher at $13.02.

Quarterly sales came in at $2.07 billion, beating stock analysts' $2 billion prediction and 27% ahead of the same period in 2020.

"Our pipeline beyond CF accelerated and delivered important clinical data in new disease areas"Adjusted earnings for the quarter also soared 34% to $3.37 per share, ahead of the $3.29 predicted by analysts.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology